TABLE 3.
Characteristics of the participants.
| Group | N | FH | FH-CHD | H | CHD |
| Variables | (n = 7) | (n = 4) | (n = 3) | (n = 6) | (n = 10) |
| Age (years) | 27 | 47.5 | 45 | 52.5 | 51.5 |
| (19–36) | (20–56) | (45–79) | (26–65) | (41–61) | |
| TC (mg/dL) | 182 | 227.5 | 176 | 194.5 | 164.5 |
| (165–187) | (171–276) | (171–232) | (148–233) | (131–233) | |
| TG (mg/dL) | 130 | 119.5 | 177 | 218.5 | 172.5 |
| (82–168) | (102–256) | (125–271) | (134–289) | (73–368) | |
| HDL (mg/dL) | 48 | 51.5 | 46 | 49 | 45 |
| (41–66) | (35–78) | (42–48) | (37–78) | (40–65) | |
| LDL (mg/dL) | 105 | 152 | 100 | 102.5 | 89 |
| (98–111) | (89–175) | (80–149) | (43–153) | (15–126) | |
| WBC (103/uL) | 7.8 | 7.5 | 7.3 | 6.1 | 5.7 |
| (3.8–12) | (5.4–8.8) | (5.4–8.5) | (5.2–9.4) | (4.9–8.6) | |
| RBC (103/uL) | 4.87 | 5.24 | 5.99 | 4.8 | 4.775 |
| (4.58–7.35) | (4.46–6.31) | (4.19–6.38) | (3.6–7.85) | (4.46–12.5) | |
| Hb (g/dL) | 14.3 | 14.4 | 13.4 | 14.35 | 14.1 |
| (10.9–18.2) | (13.9–15) | (13.3–16.2) | (11.2–14.5) | (12.5–16.2) | |
| HCT (%) | 41.9 | 42.85 | 42 | 42.25 | 41.5 |
| (32–53.7) | (39.5–43.8) | (38.3–49.7) | (32.9–44.3) | (38–46.5) | |
| Lymphocyte (%) | 35.4 | 38.3 | 28.8 | 33.2 | 35.4 |
| (25–50.3) | (25–47) | (27–34.5) | (21.4–42.2) | (22.3–40.7) | |
| Monocyte (%) | 5.2 | 4.85 | 7.2 | 6.05 | 6.65 |
| (4.6–6.9) | (4.0–6.0) | (4–8.7) | (4.5–8.8) | (5.3–9.0) |
All patients and controls were male. Data are shown as median (ranges). N, normal controls; H and CHD, patients with hyperlipidemia and coronary heart disease; respectively. FH and FH-CHD, familial hyperlipidemia and familial coronary heart disease patients, respectively. TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin; HCT, hematocrit.